View in EDS PDF Full Text

USING AGENTS THAT SUPPRESS BONE REMODELING TO TREAT OR PREVENT JOINT DISEASE: QUO VADIS?

Saved in:
Bibliographic Details
Title: USING AGENTS THAT SUPPRESS BONE REMODELING TO TREAT OR PREVENT JOINT DISEASE: QUO VADIS?
Authors: Burr, David B.1
Source: Actualizaciones en Osteología. sep-dic2016, Vol. 12 Issue 3, p197-214. 18p.
Subjects: OSTEOARTHRITIS, DIPHOSPHONATES, ESTROGEN, CARTILAGE, COLLAGEN, CHARTS, diagrams, etc.
Abstract: Treatment of osteoarthritis (OA) with antiremodeling agents has had a mixed record of results. It is likely that remodeling suppression is only effective when used in the early phases of OA, before significant progression. Animal and human studies largely bear this out. Treatment of young mice with a RANKL inhibitor suppresses bone resorption and prevents OA progression. Likewise, bisphosphonate treatments in rodents and rabbits with induced injury or inflammatory arthritis, reduced cartilage degeneration when administered preemptively, but later administration did not. The increased prevalence of OA in women after the menopause, and presence of estrogen receptors in joint tissues, suggests that treatment with estrogens or Selective Estrogen Receptor Modulators may be effective. However, in clinical trials of knee and hip, results show decreased or increased risk for OA, or no effect. Raloxifene had positive effects in animal models, but no effect in human studies. More recent potential treatments such as strontium ranelate or cathepsin-K inhibitors may be effective, but may work directly on the cartilage rather than through their well-known effects on bone. The conclusion from these studies is that anti-remodeling agents must be administered pre-emptively or in the very early stages of disease to be effective. This means that better imaging techniques or identification of early structural changes in bone that occur before progressive cartilage destruction must be developed. [ABSTRACT FROM AUTHOR]
Copyright of Actualizaciones en Osteología is the property of Asociacion Argentina de Osteologia y Metabolismo Mineral and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 122051197
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: USING AGENTS THAT SUPPRESS BONE REMODELING TO TREAT OR PREVENT JOINT DISEASE: QUO VADIS?
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Burr%2C+David+B%2E%22">Burr, David B.</searchLink><relatesTo>1</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Actualizaciones+en+Osteología%22">Actualizaciones en Osteología</searchLink>. sep-dic2016, Vol. 12 Issue 3, p197-214. 18p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22OSTEOARTHRITIS%22">OSTEOARTHRITIS</searchLink><br /><searchLink fieldCode="DE" term="%22DIPHOSPHONATES%22">DIPHOSPHONATES</searchLink><br /><searchLink fieldCode="DE" term="%22ESTROGEN%22">ESTROGEN</searchLink><br /><searchLink fieldCode="DE" term="%22CARTILAGE%22">CARTILAGE</searchLink><br /><searchLink fieldCode="DE" term="%22COLLAGEN%22">COLLAGEN</searchLink><br /><searchLink fieldCode="DE" term="%22CHARTS%2C+diagrams%2C+etc%2E%22">CHARTS, diagrams, etc.</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Treatment of osteoarthritis (OA) with antiremodeling agents has had a mixed record of results. It is likely that remodeling suppression is only effective when used in the early phases of OA, before significant progression. Animal and human studies largely bear this out. Treatment of young mice with a RANKL inhibitor suppresses bone resorption and prevents OA progression. Likewise, bisphosphonate treatments in rodents and rabbits with induced injury or inflammatory arthritis, reduced cartilage degeneration when administered preemptively, but later administration did not. The increased prevalence of OA in women after the menopause, and presence of estrogen receptors in joint tissues, suggests that treatment with estrogens or Selective Estrogen Receptor Modulators may be effective. However, in clinical trials of knee and hip, results show decreased or increased risk for OA, or no effect. Raloxifene had positive effects in animal models, but no effect in human studies. More recent potential treatments such as strontium ranelate or cathepsin-K inhibitors may be effective, but may work directly on the cartilage rather than through their well-known effects on bone. The conclusion from these studies is that anti-remodeling agents must be administered pre-emptively or in the very early stages of disease to be effective. This means that better imaging techniques or identification of early structural changes in bone that occur before progressive cartilage destruction must be developed. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Actualizaciones en Osteología is the property of Asociacion Argentina de Osteologia y Metabolismo Mineral and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=122051197
RecordInfo BibRecord:
  BibEntity:
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 18
        StartPage: 197
    Subjects:
      – SubjectFull: OSTEOARTHRITIS
        Type: general
      – SubjectFull: DIPHOSPHONATES
        Type: general
      – SubjectFull: ESTROGEN
        Type: general
      – SubjectFull: CARTILAGE
        Type: general
      – SubjectFull: COLLAGEN
        Type: general
      – SubjectFull: CHARTS, diagrams, etc.
        Type: general
    Titles:
      – TitleFull: USING AGENTS THAT SUPPRESS BONE REMODELING TO TREAT OR PREVENT JOINT DISEASE: QUO VADIS?
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Burr, David B.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: sep-dic2016
              Type: published
              Y: 2016
          Identifiers:
            – Type: issn-print
              Value: 16698975
          Numbering:
            – Type: volume
              Value: 12
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Actualizaciones en Osteología
              Type: main
ResultId 1